SASPject PT3.9 is designed for the treatment of hospital infections caused by Pseudomonas aeruginosa More: Phico Therapeutics gains £13.1m grant to advance antibacterial therapy Source: News
read moreUblituximab significantly reduced the annualised relapse rate in patients with relapsing forms of multiple sclerosis More: TG Therapeutics’ ublituximab tops Sanofi’s Aubagio in MS trial Source: News
read moreJCVI advises pregnant women in the UK be offered COVID-19 vaccination at the same time as the rest of the population More: New advice on COVID-19 vaccination for pregnant women in UK Source: News
read moreSarclisa has been approved in combination with a standard of care regimen for relapsed multiple myeloma More: EC approves new Sarclisa indication Source: News
read moreModerna cuts COVID-19 vaccine deliveries to Canada, U.K. amid European supply struggles nhigginsdunn Fri, 04/16/2021 – 16:07 More: Moderna cuts COVID-19 vaccine deliveries to Canada, U.K. amid European supply struggles Source: fierce
read moreSanofi bags oral rival to Novartis’ injectable blockbuster Cosentyx ntaylor Fri, 04/16/2021 – 12:54 More: Sanofi bags oral rival to Novartis' injectable blockbuster Cosentyx Source: fierce
read more© 1994 - 2026 B.M. Pharmaceuticals